Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

chronic lung disease

- PMLiVE

AstraZeneca launches diabetes portal in Germany

Zuckerkrank.de is designed to educate patients and families

- PMLiVE

AZ takes asthma antibody into phase III

Tralokinumab tipped as potential blockbuster

- PMLiVE

Phase III data back AZ’s gout drug

Lesinurad on course to be filed this year

- PMLiVE

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

Will boost its pipeline prospects and inhaled device capabilities

- PMLiVE

AZ signs two companion diagnostic deals

Will help identify patients suitable for treatment with lung cancer drugs

- PMLiVE

AstraZeneca steps up cancer immunotherapy research

MedImmune unit will study anti-PD1 drug in combination with Advaxis’ cervical cancer vaccine

- PMLiVE

AZ unveils plans for new Cambridge HQ

Construction of its Cambridge Biomedical Campus will start early next year

- PMLiVE

AZ sues to block generic saxagliptin from Mylan

Attempt to protect diabetes treatments Onglyza and Kombiglyze XR

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

AZ expands its mHealth services with new COPD initiative

Partners with Exco InTouch to launch Me&MyCOPD programme

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

AstraZeneca has clearer route to Movantik approval in US

Won't have to carry out cardiovascular outcomes study prior to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links